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Abstract
Background: Hyperglycemia-induced oxidative stress plays a central role in the development of diabetic myocardial
complications. Adiponectin (APN), an adipokine with anti-diabetic and anti-ischemic effects, is decreased in diabetes. It is
unknown whether or not antioxidant treatment with N-acetylcysteine (NAC) and/or allopurinol (ALP) can attenuate APN
deficiency and myocardial ischemia reperfusion (MI/R) injury in the early stage of diabetes.
Methodology/Principal Findings: Control or streptozotocin (STZ)-induced diabetic rats were either untreated (C, D) or
treated with NAC (1.5 g/kg/day) or ALP (100 mg/kg/day) or their combination for four weeks starting one week after STZ
injection. Plasma and cardiac biochemical parameters were measured after the completion of treatment, and the rats were
subjected to MI/R by occluding the left anterior descending artery for 30 min followed by 2 h reperfusion. Plasma and
cardiac APN levels were decreased in diabetic rats accompanied by decreased cardiac APN receptor 2 (AdipoR2), reduced
phosphorylation of Akt, signal transducer and activator of transcription 3 (STAT3) and endothelial nitric oxide synthase
(eNOS) but increased IL-6 and TNF-a (all P,0.05 vs. C). NAC but not ALP increased cardiac APN concentrations and AdipoR2
expression in diabetic rats. ALP enhanced the effects of NAC in restoring cardiac AdipoR2 and phosphorylation of Akt,
STAT3 and eNOS in diabetic rats. Further, NAC and ALP, respectively, decreased postischemic myocardial infarct size and
creatinine kinase-MB (CK-MB) release in diabetic rats, while their combination conferred synergistic protective effects. In
addition, exposure of cultured rat cardiomyocytes to high glucose resulted in significant reduction of cardiomyocyte APN
concentration and AdipoR2 protein expression. APN supplementation restored high glucose induced AdipoR2 reduction in
cardiomyocytes.
Conclusions/Significance: NAC and ALP synergistically restore myocardial APN and AdipoR2 mediated eNOS activation.
This may represent the mechanism through which NAC and ALP combination greatly reduces MI/R injury in early diabetic
rats.
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Introduction
Ischemic heart disease (IHD) is a major perioperative
complication that is associated with significant morbidity and
mortality, particularly in patients with diabetes [1]. Hyperglyce-
mia-induced oxidative stress plays a central role in the develop-
ment and progression of IHD in diabetes [2]. Mortality following
myocardial infarction can be significantly reduced by procedures
that allow the rapid return of blood flow to the ischemic zone of
the myocardium, i.e., reperfusion therapy. However paradoxically,
despite the restoration of coronary flow, reperfusion after a
prolonged period of ischemia aggravates oxidative stress which is a
major cause of myocardial injury. Recently, antioxidant therapy
has become a promising pharmacological approach for the
prevention of myocardial ischemia/reperfusion (MI/R) injury
[3]. Although the rationale for the use of antioxidants is strong,
antioxidant therapy with classic antioxidants in high-risk diabetic
patients hasn’t shown any beneficial effects on microvascular and
macrovascular events [4]. Consequently, increasing attention has
been paid to the development of interventions to decrease the risk
of cardiovascular complications in diabetes.
In the myocardium, NADPH oxidase and xanthine oxidase are
the two major enzymatic sources of reactive oxygen species (ROS)
[5,6]. N-acetylcysteine (NAC), the N-acetyl derivative of the amino
acid cysteine, reduced NADPH oxidase activity [7]. However,
NAC attenuated, but did not prevent myocardial dysfunction in
diabetic rat hearts [7]. Allopurinol (ALP), a xanthine oxidase (XO)
inhibitor, attenuated the diabetes-induced increased myocardial
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nitrosative stress, improving diabetes-induced cardiac dysfunction
[9]. As NAC and ALP target different components of ROS, it is
conceivable that NAC and ALP may synergistically reduce cardiac
complications induced by oxidative stress, particularly in MI/R
injury in diabetes.
Oxidative stress, even of short duration, can decrease the
production of adiponectin (APN) [10], an adipocyte-derived
plasma protein with anti-diabetic and anti-inflammatory proper-
ties [11,12]. Plasma APN levels are decreased in patients with
diabetes [13]. Deficiency in APN led to increased myocardial
damage in response to ischemic insult and APN supplementation
increased nitric oxide (NO) production and attenuates MI/R
injury [14,15]. APN can increase NO production by activating
endothelial nitric oxide synthase (eNOS) [16]. However, in
diabetes, myocardial eNOS protein expression is progressively
reduced with increased nitrative and oxidative stress, while
myocardial NO content is decreased [17]. In addition, studies
have shown that APN may modulate oxidative stress and protect
the heart from injury [18]. These investigations suggest that
effective restoration of APN production by antioxidants could lead
to attenuation or prevention of MI/R injury in diabetes.
Therefore, we hypothesized that NAC and ALP may synergize in
reducing MI/R injury in diabetes, primarily through restoration of
APN production or activation. We investigated the effects of
antioxidants NAC and/or ALP on cardiac APN content and its
receptors mediated signaling cascades and the effect on MI/R injury
in the early stage of streptozotocin (STZ)-induced diabetic rats.
Materials and Methods
Induction of diabetes
Male Sprague Dawley rats (250610 g, 6–8 weeks) obtained
from the Laboratory Animal Service Center (University of Hong
Kong) were used in this study. All rats were housed and given free
access to standard rat chow and water in accordance with the
principles of Animal Care of the University of Hong Kong. The
experimental protocol used in this study was approved by the
Committee on the Use of Live Animals in Teaching and Research
(CULATR). Diabetes was induced by a single tail vein injection of
STZ at the dose of 65 mg/kg bodyweight (Sigma-Aldrich, St.
Louis, MO) in 0.1 M citrate buffer (pH 4.5) or citrate buffer alone
as control under anesthesia with a combination of ketamine
67.7 mg/kg bodyweight and xylazine 6.77 mg/kg bodyweight.
After 72 hours injection, blood glucose was measured using a One
Touch Ultra Glucose meter (Life Scan Inc. USA) and rats with
blood glucose levels over 15 mM were considered diabetic.
Experimental protocol
Rats were randomly divided into five groups, control (C);
diabetes (D); diabetes treated with NAC (Sigma-Aldrich, St. Louis,
MO) (D+N); diabetes treated with ALP (Sigma-Aldrich, St. Louis,
MO) (D+A) or their combination (D+N+A). The chemicals were
dissolved in drinking water for 4-weeks duration of treatment
starting one week after induction of diabetes. We adopted a dose of
NAC at 1.5 g/kg/day, as our previous study has reported that
NAC at the dose of 1.4–1.5 g/kg/day completely prevented
hyperglycemia-induced oxidative stress after 8-week of STZ
induction [19]. Also, the dose of ALP was adjusted to give a daily
intake of 100 mg/kg/day in diabetic rats as described [20].
During the treatment period, general characteristics including
water intake was assessed on a daily basis, while food consumption
and body weight were monitored weekly. Plasma glucose levels
(mM) were evaluated weekly using the One Touch glucometer
(Life Scan Inc.USA). At termination (5-weeks after the onset of
diabetes), rats were weighed and then euthanized with an
intraperitoneal injection of pentobarbital sodium (65 mg/kg body
weight). A blood sample was collected from the inferior vena cava,
and plasma was extracted and stored at 280uC until further
analysis. Hearts were removed from the chest and rinsed with ice-
cold phosphate buffered saline, and weighed. The remaining
ventricular tissue was immediately frozen in liquid nitrogen and
stored at 280uC until assayed.
The subgroups of rats were subjected to MI/R by occluding the
left anterior descending (LAD) artery for 30 min followed by 2 h
reperfusion and myocardial infarction was determined as de-
scribed below.
Plasma and cardiac levels of free 15-F2t-isoprostane (15-
F2t-IsoP)
Free 15-F2t-IsoP, a specific marker of oxidative stress in vivo
originally produced by the random oxidation of tissue phospho-
lipids, was measured by using an enzyme immunoassay kit
(Cayman chemical, Ann Arbor, MI) as described [21]. Plasma
samples and heart tissue homogenates (in PBS) were purified using
Affinity Column and Affinity Sorbent (Cayman chemical, Ann
Arbor, MI). The absorbance from the enzymatic reaction was
detected at 412 nm. The values of plasma or cardiac free 15-F2t-
IsoP were expressed as pg/mL in plasma or pg/g heart tissue in
cardiac homogenates, respectively.
Measurements of plasma and cardiac APN level
Plasma and cardiac APN levels were measured using a
commercially available APN enzyme-linked immunosorbent assay
(ELISA) kit (AdipoGen, Inc. Incheon, South Korea) following the
manufacturer’s protocol. In brief, frozen heart tissue or primarily
cultured cardiomyocytes were homogenized at 4uC in cold buffer
(20 mmol/L Tris-HCl, pH 7.5, 50 mmol/L 2-mercaptoethanol,
5 mmol/L EGTA, 2 mmol/L EDTA, 1 mmol/L PMSF,
10 mmol/L NaF, 25 mg/mL leupeptin, 2 mg/mL aprotinin) and
then centrifuged at 1500 g for 5 minutes at 4uC. The supernatant
was collected and stored at 280uC until analyses were conducted.
The protein content of the samples was measured using the Bio-
Rad protein assay kit with the use of bovine serum albumin as a
standard. The values of plasma or cardiac APN were expressed as
mg/mL in plasma or mg/mg in heart tissue or ng/mg in
cardiomyocytes, respectively.
Plasma biochemical analysis
Plasma TNF-a levels were determined using a rat TNF-a
ELISA kit (eBiosource International, Burlington, Ontario, Cana-
da). Plasma IL-6 levels were measured using a commercially
available ELISA kit (eBiosource International, Burlington, On-
tario, Canada). Plasma creatinine kinase-MB (CK-MB) levels were
determined using a commercially available rat ELISA kit (R&D
Systems, Minneapolis, MN).
RNA extraction and RT-PCR
Total RNAs from heart tissue were extracted using TRIZOL
obtained from Invitrogen (Carlsbad, Calif) following the protocol
provided by the manufacturer. Extracted RNA was reverse
transcribed to cDNA with the SuperScript
TM II RNase H Reverse
Transcriptase (Invitrogen, Carlsbad, Calif). Synthesized cDNA
was amplified by Platinum TaqPCRx DNA Polymerase (Invitro-
gen, Carlsbad, Calif). Specific primers for APN: APN forward
CTCCACCCAAGGAAACTTGT; APN reverse CTGGTCCA-
CATTTTTTTCCT. PCR conditions for APN were 30 s at 94uC,
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housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), served as internal control.
Immunoprecipitation and western blot analysis
Frozen ventricular tissue samples (n=6 rats/group) were
homogenized in lysis buffer (20 mmol/L Tris-HCl pH=7.5,
50 mmol/L 2-mercaptoethanol, 5 mmol/L EGTA, 2 mmol/L
EDTA, 1% NP40, 0.1% SDS, 0.5% deoxycholic acid, 10 mmol/L
NaF, 1 mmol/L PMSF, 25 mg/mL leupeptin, 2 mg/mL aproti-
nin), and protein concentrations were determined as previously
described [22]. For direct immunoblotting, aliquots of lysate were
mixed with 56loading buffer containing 2-mercaptoethanol and
maintained at 100uC for 10 min before loading on 10% SDS-
PAGE. Following SDS-PAGE separation, proteins were trans-
ferred to PVDF membrane. Membranes were blocked in TBST
containing 5% (w/v) non-fat milk and dried for 1 hour at room
temperature [23]. Membrane strips were incubated with primary
antibodies overnight at 4uC at the following dilutions: APN
receptor 1 (AdipoR1) and APN receptor 2 (AdipoR2) (Santa Cruz
Biotechnology, Santa Cruz, CA) 1:500; total adenosine mono-
phosphate–activated protein kinase-alpha (AMPK-a), Akt, signal
transducer and activator of transcription 3 (STAT3), eNOS and
GAPDH (Cell Signaling Technology, Beverly, MA) 1:1000;
phospho-AMPK-a, phospho-Akt (Ser 473), phospho-STAT3
(Ser 727) and phospho-eNOS (Ser 1177) (Cell Signaling
Technology, Beverly, MA) 1:500. Following extensive washing,
membrane strips were incubated with a 1:5000 anti-rabbit IgG
(Cell Signaling Technology, Inc. MA) conjugated to horseradish
peroxidase for 1 h. Protein bands were detected by a standard
ECL method and images were measured by a densitometer with
analysis software.
Myocardial infarction and infarct size determination in
vivo
After the completion of NAC and/or ALP treatments (5-weeks
after the onset of diabetes), rats in the respective subgroups (n=7/
group) were anesthetized by intraperitoneal injection of sodium
pentobarbital (65 mg/kg) and the trachea was cannulated with a
polyethylene tube connected to a respirator with a tidal volume of
4 mL (60 breaths/min). Then left thoracotomy was performed
between the fourth and fifth ribs. The pericardial tissue was
removed under a microscope and the LAD artery was ligated with
8-0 silk suture using a snare occluder [24]. The rats were then
subjected to 30 min of LAD ligation followed by 120 min of
reperfusion. At the end of each experiment, myocardial infarct size
was measured using TTC (1% 2,3,5-triphenyltetrazolium chloride)
staining as described [25]. Briefly, the LAD was reoccluded and
cannulated just distal to the occlusion site. Ten milliliters of saline
and 10 mL of patent blue dye were injected at equal pressure into
the LAD and left atrium, respectively, to delineate the anatomic
area at risk (AAR) subjected to prolonged occlusion and
reperfusion and the nonischemic normal zone. The heart was
immediately fibrillated, removed, and sliced into serial transverse
sections 6 to 7 mm in width. The unstained AAR was separated
from the blue stained normal area, and the two regions were
incubated at 37uC for 20 to 30 min in 1% TTC in 0.1 mol/L
phosphate buffer adjusted to pH 7.4. TTC stains noninfarcted
myocardium a brick red color because of the presence of a
formazin precipitate, resulting from reduction of TTC by
dehydrogenase enzymes present in viable tissue. Infarcted
myocardium remains unstained. Infarcted and noninfarcted
myocardium within the AAR were carefully separated and
weighed after overnight storage in 10% formaldehyde. Infarct
size (IS) was expressed as a percentage of the AAR.
Hemodynamics were continuously monitored using subcutane-
ous stainless-steel electrodes that were connected via a cable to a
PowerLab monitoring system (ML750 PowerLab/4sp with
MLT0380 Reusable BP Transducer; AD Instruments, CO
Springs, CO).
Rat cardiomyocytes isolation and cell treatment
Calcium-tolerant cardiac myocytes were prepared from adult
male Sprague-Dawley rat ventricles using a modified method as
described [26]. Briefly, rats were anesthetized and heparinized.
The hearts were rapidly removed and mounted on a Langendorff
perfusion apparatus, and immediately perfused with Ca
2+-free
buffer containing (in mmol/L) 120.4 NaCl, 14.7 KCl, 0.6
KH2PO4, 0.6 Na2HPO4, 1.2 MgSO4?7H2O, 10 Na-HEPES, 4.6
NaHCO3, 30 Taurine, 10 2,3-butanedione monoxime (BDM), 5.5
glucose (pH 7.1, 37uC). Enzymatic digestion was initiated by
adding 1.5 mg/mL collagenase II (Invitrogen, Carlsbad, Calif)
and CaCl2 (50 mM) to the perfusion solution. Following 20 min of
digestion, the ventricle was quickly removed and gently teased into
small pieces with fine forceps in the perfusion solution with 10%
calf serum and 12.5 mM CaCl2. The solution was filtered with
70 mm nylon cell strainer (Fisher Scientific, Waltham, MA) to
exclude un-digested tissues. After the cardiomyocytes were pelleted
by gravity for 10 min, the supernatant was aspirated and the
cardiomyocytes were resuspended with M199 medium with
selenium/insulin/transferring (Sigma-Aldrich, St. Louis, MO) in
6-well polystyrene plates precoated with Matrigel. The final cell
suspension, which contained about 70–80% viable myocytes, was
subjected to the following experiments.
Recombinant adenoviruses for expression of either APN (Adv-
APN) or control luciferase (Adv-Luc) was synthesized as described
[27]. The cultured cardiomyocytes were infected with these
adenoviruses at a multiplicity of infection of 50 as previously
reported [28]. The cardiomyocyte preparations were randomly
divided into four groups and treated as follows: (1) normal D-
glucose (5.5 mM) medium as control group (C); (2) high D-glucose
(25 mM) medium (H-G); (3) H-G group treated with Adv-APN
(H-G+APN); (4) H-G group treated with Adv-Luc (H-G+Luc).
After 48 h incubation, cells were collected and stored at 280uC
until analyzed for APN concentration and AdipoR1 and AdipoR2
protein expression, respectively using ELISA and western blotting
assays as described above.
Statistical analysis
All the values are expressed as mean 6 standard error of the
mean (S.E.M.). One-way analysis of variance (ANOVA) was used
for statistical analyses (GraphPad Prism, USA) of data obtained
within the same group of rats and between groups of rats,
respectively, followed by Tukey’s test for multiple comparisons of
group means. P,0.05 was considered statistically significant.
Results
General characteristics and plasma glucose levels
STZ-induced diabetic rats display hyperglycemia, polydipsia
and polyphagia evidenced as significantly increased plasma
glucose, water intake and food consumption, compared with
age-matched controls (all P,0.05, Table 1). Treatment with NAC
alone or NAC in combination with ALP markedly reduced food
consumption and water intake (P,0.05), while ALP treatment
alone slightly decreased water and food consumption. Both the
body weight and heart weight in the diabetic group were lower
Antioxidants Restore Diabetic Heart Adiponectin
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weight ratio in the diabetic group were higher than that in the
control group (P,0.05). Although neither NAC alone nor the
combination with ALP had a significant impact on body weight in
diabetic rats, they prevented the increase in heart to body weight
ratio seen in the diabetic group and normalized it to a level
comparable to that in the control group (P,0.05, D+No rD +N+A
vs. D). However, ALP alone had no effect on diabetic body weight
and heart to body weight ratio. Plasma glucose was significantly
elevated in the diabetic group as compared to that in the control.
Neither NAC/ALP alone nor their combination had a significant
impact on glucose level in diabetic rats.
Oxidative stress marker free 15-F2t-IsoP levels
As shown in Fig. 1A and 1B, both plasma and the cardiac tissue
levels of free 15-F2t-IsoP were significantly elevated in diabetic rats
compared to that of control rats (all P,0.01). NAC and ALP
significantly reduced the level of free15-F2t-IsoP both in plasma and
cardiac tissue (all P,0.05 vs. D). NAC in combination with ALP did
not further reduce plasma and cardiac tissue free15-F2t-IsoP.
Plasma IL-6 and TNF-a
Because APN is a protein with anti-inflammatory properties
[29], we determined plasma IL-6 and TNF-a levels in control and
diabetic rats with or without anti-oxidant treatment. As shown in
Fig. 1C and 1D, plasma IL-6 and TNF-a levels were increased in
the rats with diabetes. NAC and/or ALP treatment significantly
reduced plasma IL-6 level in D rats, but had no synergistic effects.
NAC significantly decreased plasma TNF-a level in D rats to a
level comparable to that in the control group (P,0.01 D+N vs. D,
P.0.05 D+N vs. C) while ALP had no significant effect on plasma
TNF-a. Of note, NAC in combination with ALP evidently
decreased plasma TNF-a in D rats (P,0.05 D+N+A vs. D) but the
level remained significantly higher than that in the control
(P,0.01 D+N+A vs. C, Fig. 1D).
Cardiac and/or plasma APN expression/secretion
To investigate whether the cardiac and/or plasma levels of APN
are altered in rats in early stage of diabetes and whether or not
they can be affected by antioxidants, we observed the effects of
NAC and/or ALP on cardiac and plasma levels of APN in rats
Table 1. General characteristics after STZ treatment at termination of study.
Parameters C D D+ND +AD +N+A




Food consumption (g/kg/day) 68.564.7 179.1613.3* 137.6613.6*
# 175.769.5* 158.869.06*
#
Body weight (g) 489.7615.3 314.969.5* 297.1610.7* 295.6615.6* 292.6618.4*
Plasma glucose (mM) 6.260.3 28.461.1* 28.761.1* 27.861.1* 28.061.2*
Heart/Body weight ratio (g/kg) 3.560.2 4.360.3* 3.660.1
# 4.160.2 3.760.2
#
All values are expressed as Mean 6 S.E.M. n=7 per group. Water intake and food consumption were the average value of four weeks. Body weight, plasma glucose and




Figure 1. Plasma and cardiac tissue levels of 15-F2t-Isoprostane (15-F2t-Isop, A and B) and plasma levels of interleukin-6 (IL-6, C)
and tumor necrosis factor-a (TNF-a, D) in control and diabetic rats with or without antioxidants treatment. Data are expressed as mean
6 SEM (n=7 per group), **P,0.01 vs. C group;
#P,0.05,
##P,0.01 vs. D group.
&P,0.05 vs. D+N group.
doi:10.1371/journal.pone.0023967.g001
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plasma and cardiac APN levels at the 4
th week were decreased in
D rats (P,0.01 vs. C). NAC partially but significantly restored
cardiac APN concentration (P,0.05), but did not affect plasma
APN level in D rats. ALP had no effect per se, but potentiated the
beneficial effect of NAC on cardiac APN (P,0.05, D+N+Av s
D+N). Changes in cardiac APN mRNA expression in various
groups basically mirrored the changes in cardiac APN protein
expression (Fig. 2C).
APN receptors and the downstream signaling pathways
AdipoR1 and AdipoR2 serve as receptors for APN and mediate
APN-related signaling pathways. We further investigated whether
or not cardiac APN receptors and the downstream signaling
proteins are altered in diabetic rats and whether they can be
affected by antioxidants. As shown in Fig. 2D, the expression of
cardiac AdipoR1 was increased in the early stage of rat diabetes
compared with control rats, which was similar to the findings [30]
observed in the late stage (8-weeks) of STZ-diabetic models.
However, AdipoR2 expression was decreased in D rats (P,0.05
vs. C) (Fig. 2E). NAC but not ALP increased cardiac AdipoR2
expression (P,0.05), while neither of them affected cardiac
AdipoR1 in D rats. ALP enhanced the effect of NAC in increasing
cardiac AdipoR2 expression (P,0.05, D+N+A vs. D+N).
AMPK consists of one catalytic subunit (a) which plays an
important role in cardiac metabolism and cardiomyocyte survival
response to ischemia. Deficiency in APN resulted in AMPK-a
inactivation at the late stage of STZ-diabetic rats [30]. However, it
is unknown whether AMPK-a activation was altered in the early
stage of diabetes and whether or not it could be affected by
antioxidants. Therefore, we examined the cardiac AMPK-a
protein expression and its phosphorylation status at Thr172 (p-
AMPK-a, Thr172) as well as its downstream factor acetyl-CoA
carboxylase (ACC). In contrast to its changes in the myocardium
in the later stage of rat diabetes (15), cardiac phosphorylation of
AMPK-a was significantly increased in the myocardium of early
diabetic rats which was accompanied by increased ACC
phosphorylation as compared with control rats (all P,0.05 vs.
Figure 2. Plasma and cardiac adiponectin (APN) and myocardial APN receptors expression in control and diabetic rats with or
without antioxidants treatment. A. Plasma APN levels. B. Cardiac APN levels. C. Cardiac APN mRNA expression. D. Cardiac AdipoR1 protein
expression. E. Cardiac AdipoR2 protein expression. Data are expressed as mean 6 SEM (n=7 per group), *P,0.05, **p,0.01 vs. C group;
#P,0.05,
##P,0.01 vs. D group;
&P,0.05 vs. D+N group.
doi:10.1371/journal.pone.0023967.g002
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ylation at Thr-172, was attenuated by treatment with either NAC
or ALP or their combination (all P,0.05, vs. D) although levels of
p-AMPK-a at Thr-172 were still higher than that in the control.
Of interest, neither NAC nor ALP alone had significant effects on
enhanced ACC, while their combination significantly attenuated
the increase in ACC phosphorylation seen in D rats.
Studies show that phosphoinositide 3-kinase (PI3K)/Akt and
janus kinase 2 (JAK2)/STAT3 signaling pathways may be
involved in antioxidant-mediated NO production and subsequent-
ly contribute to myocardial protection from ischemia reperfusion.
Furthermore, APN exerts its cardioprotection via eNOS mediated
restoration of NO production. We, therefore, investigated changes
in myocardial protein levels of Akt, STAT3 and eNOS as well as
their phosphorylation status. As shown in Fig. 3C, 3D and 3E,
myocardial phosphorylation of Akt, STAT3 and eNOS was
significantly down-regulated in diabetic rats compared to control
(P,0.05). Both NAC and ALP restored Akt and eNOS
phosphorylation, while the combination conferred synergistic
effects (P,0.05, D+N+A vs. D+N). NAC but not ALP restored
STAT3 phosphorylation. STAT3 phosphorylation in the NAC
and ALP combination group is about 1.2-fold of that in the D+N
group, but the difference did not reach statistical significance.
Hemodynamics and infarct size
To determine if antioxidants can attenuate MI/R injury in
diabetes, we measured the hemodynamics and IS in the diabetic
rats with or without antioxidants treatment. As shown in Table 2,
baseline hemodynamic data were similar among groups, but a few
significant (P,0.05) differences were observed (Table 2). Heart
rate (HR) at baseline was not different among the five
experimental groups. Coronary artery occlusion (ischemia)
significantly decreased mean arterial pressure (MAP) and rate-
pressure product (RPP) in all groups in comparison with baseline
Figure 3. Cardiac protein expression of AMPK (A), ACC (B), Akt (C), STAT3 (D) and eNOS (E) and their phosphorylation status in
control and diabetic rats with or without antioxidants treatment. Mean band density was normalized relative to GAPDH. Data are expressed
as mean 6 SEM (n=7 per group), *P,0.05, **P,0.01 vs. C group;
#P,0.05,
##p,0.01 vs. D group;
&P,0.05 vs. D+N group.
doi:10.1371/journal.pone.0023967.g003
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between groups during ischemia and reperfusion. Combined NAC
and ALP treatment facilitated recovery of MAP after reperfusion
as compared to the diabetic untreated group.
The IS is shown in Fig. 4A. Coronary occlusion followed by
reperfusion resulted in an IS of 45.3614% of area at risk in
control group and 49.765.9% in diabetic rats (P.0.05 D vs. C).
NAC and ALP reduced IS to 22.169.9% (P,0.01) or
26.1612.7%, respectively, as compared with the D group (all
P,0.05 vs. D). The combination of NAC and ALP conferred a
synergistic effect and further decreased IS to 14.963.0% (P,0.01
D+N+A vs. D, P,0.05 D+N+A vs. D+No rD +A).
Plasma CK-MB levels
CK-MB isoenzyme is a major biomarker for myocardial cellular
injury. As shown in Fig. 4B, there were no differences in CK-MB
release among experimental groups before coronary occlusion.
However, ischemia followed by reperfusion significantly increased
plasma CK-MB concentration from 35.861.2 U/L to
41.462.5 U/L (P,0.05) in group C. Postischemic plasma CK-
MB level after 2 hours reperfusion was significantly higher in D
rats (P,0.05 D vs. C, Fig. 4B) which corresponded to a larger IS in
D rats compared to C (Fig. 2A). NAC or ALP significantly reduced
postischemic CK-MB release in D rats. The combination of NAC
and ALP conferred a synergistic effect in attenuating postischemic
CK-MB release in D rats to such a degree that by 2 h post-
reperfusion, plasma CK-MB levels in the D+N+A group was
similar to that before ischemia (P.0.05).
Effects of cardiac APN on AdipoR2 expression in rat
cardiomyocytes under high-glucose
To determine whether or not cardiac APN level can affect the
expression of APN receptors in diabetes, APN was supplied using
an adenoviral transfection system into primary cultured rat
cardiomyocytes under high glucose. As shown in Fig. 5A and
5B, both APN level and AdipoR2 protein expression in
cardiomyocytes were significantly decreased after high glucose
treatment for 48 h (P,0.05). Supplementation of APN to
cardiomyocytes exposed to under high-glucose stimulation re-
stored AdipoR2 protein expression to a level comparable to that in
the control (P,0.05 H-G+Adv-APN vs. H-G; P.0.05, H-G+APN
vs. C). However, cardiomyocyte AdipoR1 protein expression was
not significantly altered after high-glucose treatment, nor was it
affected by APN supplementation (Fig. 5B).
Discussion
In this study, we have shown that both plasma and cardiac APN
levels were decreased significantly in the early stage of type 1
diabetes in rats. NAC but not ALP increased cardiac APN
Table 2. Hemodynamics at baseline, at 15 min of ischemia, at
1 h of reperfusion, and at 2 h of reperfusion in diabetic rats
with or without antioxidants treatment.




C 275612 125643 4 61
D 303613 117633 6 62
D+N 308616 117663 6 61
D+A 318691 1 7 683 8 63
D+N+A 309610 117643 7 62
Ischemia





D+A 286625 93610 2864
D+N+A 294617 9768** 2862*
1 h reperfusion
C 269614 9565** 2561**




D+A 311614 8769* 2963
D+N+A 310618 9068** 2763*
2 h reperfusion
C 290622 9067** 2663*
D 290677 5 63**
# 2461**
D+N 308697 9 63**
# 2661**
D+A 309613 8469** 2562*
D+N+A 300614 8566** 2462**
All values are expressed as Mean 6 S.E.M. n=7 per group. HR, MAP and RPP
were measured at baseline and during ischemia
*P,0.05,
**P,0.01 vs. their corresponding baseline;
#P,0.05 vs. their corresponding C groups.
doi:10.1371/journal.pone.0023967.t002
Figure 4. Myocardial ischemia reperfusion injury assessed after
30 min ischemia followed by 2 h reperfusion in control and
diabetic rats with or without antioxidants treatment. A. Percent
infarct size (IS) expressed as a percentage of the area at risk (AAR). Data
are expressed as mean 6 SEM (n=7 per group). *p,0.05 vs. C group;
#p,0.05,
##p,0.01 vs. D group;
&P,0.05 vs. D+N group. B. Plsma CK-
MB secretion assessed by ELISA kit. Data are expressed as mean 6 SEM
(n=7 per group). *p,0.05, **p,0.01 vs. C group before ischemia;
&p,0.05 vs. C group after 2 h reperfusion;
#p,0.05,
##p,0.01 vs. D
group after 2 h reperfusion.
doi:10.1371/journal.pone.0023967.g004
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effects of NAC. To our knowledge, this is the first study to
investigate the changes of cardiac APN level and its receptors in
diabetic rats and the effectiveness of antioxidant treatment. Both
NAC and ALP treatment decreased postischemic myocardial
infarct size in the rats with diabetes respectively, while their
combination conferred a synergistic effect in attenuating postis-
chemic myocardial injury in diabetes. Further, we have shown that
in cultured cardiomyocytes, high glucose exposure decreased
cardiomyocyte AdipoR2 protein expression, which can be restored
by APN supplementation.
It has been reported that oxidative stress negatively modulates
APN gene expression [31], which means that APN could be
decreased in diabetes as a result of hyperglycemia-induced
oxidative stress. In STZ-induced type 1 diabetic rats, we found
that both plasma and cardiac APN levels at the 4
th week were
decreased compared with non-diabetic rats. Although some studies
have shown that plasma APN levels are increased in type 1
diabetic patients, our study and other studies [30,32] showed
decreased plasma APN levels in type 1 diabetic rats and the
reasons for this discrepancy may be due to species differences. As
reported, constant high glucose significantly reduced APN protein
expression and secretion compared to normal glucose conditions
and this effect seems to be related to over-production of ROS,
which can be attenuated by treatment with NAC [33]. Our study
also showed that NAC restored cardiac APN concentrations, but
did not affect plasma APN levels in rats with diabetes. Although
ALP, similar to NAC, decreased oxidative stress biomarker free
15-F2t-Isop levels in plasma and cardiac tissue, ALP had no direct
effect but potentiated the effect of NAC in enhancing cardiac APN
levels. The reasons for this discrepancy between NAC and ALP
remains unclear and merits further study. A possible explanation
could be that NAC and ALP exert their antioxidant effect by
targeting different initial activators which may have disparate
effects in regulating APN expression. Of note, the inability of ALP
to restore APN levels may explain why ALP treatment didn’t
prevent the development of myocardial hypertrophy in diabetic
rats as evidenced by the increased heart-to-body weight ratio in
the current study. It was reported that APN protects against the
development of cardiac hypertrophy in diabetes [34]. Interesting-
ly, despite of their similar antioxidant effectiveness in attenuating
hyperglycemia-induced oxidative stress evidenced as reductions in
plasma and cardiac levels of 15-F2t-IsoP, the effectiveness of NAC
and ALP on heart weight and water intake varies. This may be
potentially resulted from their different effects on secretion or
sensitivity of APN, which can exert ameliorative effects on various
symptoms of diabetes such as polydipsia and polyphagia via its
anti-diabetic property. However, these hypotheses need to be
further studied.
The proinflammatory cytokines TNF-a and IL-6 have been
shown to both suppress and antagonize the action of APN in
diabetes [35,36]. In this study, both plasma TNF-a and IL-6 levels
were significantly increased in rats with diabetes, which may
contribute to the decreased plasma APN level in diabetes. Both
NAC and ALP significantly decreased plasma IL-6 secretion in
diabetes, but the combination conferred no further benefit. Of
note, NAC alone but not ALP significantly decreased plasma
TNF-a levels in group D. To be more precise, NAC treatment
normalized plasma TNF-a to a level comparable to that in the
control group. Notably, ALP partially attenuated the effect of
NAC in decreasing plasma TNF-a levels, as such the plasma TNF-
a concentration in the NAC and ALP combination group was
significantly lower than that in group D but higher than that in
NAC treated and in control group. This is an intriguing finding.
The reason why ALP compromised NAC’s effect in reducing
TNF-a is not very clear. The ALP inhibition of xanthine oxidase
activity should have altered the production of its metabolite uric
acid, the later has been shown to react with NAC [37], which may
potentially affect some of NAC’s effects. Although plasma TNF-a
concentrations were not completely consistent with plasma APN
changes after antioxidant treatment in our study, the changes of
plasma TNF-a seem to be inversely correlated to changes in
cardiac APN levels. It is possible that, in diabetes, the cardiac
origin of APN may play an important role in regulating systemic
TNF-a. Study has shown that APN knockout mice exhibited high
plasma TNF-a concentration [38] while supplementation of
plasma APN decreased TNF-a in APN knockout mice, which
supports the notion that APN can directly suppress TNF-a
[39,40]. These investigations by others and our current study
demonstrated an anti-inflammatory effect of APN.
Studies have shown APN exerts its cardioprotective effect
through AdipoR1 and AdipoR2, which are both expressed in the
intact heart [41] and in cardiomyocytes [42]. AdipoR1 and
AdipioR2 can be regulated under physiological and pathophysi-
ological states, such as fasting [43], insulin [44], hyperglycemia
[43,45]. Current in vivo and in vitro studies showed that cardiac
AdipoR2 protein expression was decreased under high glucose
stimulation. However, cardiac AdipoR1 protein expression was
increased in the in vivo model but not in cultured cardiomyocytes
exposed to high glucose. The increased cardiac protein expression
Figure 5. Cardiac adiponectin (APN) level affects cardiac APN receptors expression in rat myocardiocytes under high-glucose. A.
Cardiomyocytes APN levels. B. Cardiomyocytes AdipoR1/2 protein expression. Data are expressed as mean 6 SEM (n=5 per group), *P,0.05 vs. C
group;
#P,0.05 vs. H-G group.
doi:10.1371/journal.pone.0023967.g005
Antioxidants Restore Diabetic Heart Adiponectin
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23967of AdipoR1 in diabetic rats may be a compensatory mechanism in
response to decreased plasma and cardiac APN in the early stage
of diabetes. NAC restored cardiac AdipoR2 expression, but did
not affect cardiac AdipoR1 in diabetic rats. ALP had no effect
itself, but potentiated the beneficial effect of NAC on cardiac
AdipoR2 expression. Taken together, these findings suggest that
enhancements of APN and cardiac AdipoR2 may represent the
major mechanisms by which NAC or NAC and ALP combination
confer cardioprotection in early diabetes. In addition, the good
agreement between cardiac APN level and AdipoR2 expression in
diabetic rats suggests that cardiac APN level may directly affects
cardiac AdipoR2 expression under hyperglycemia. Indeed, our in
vitro study demonstrated that high-glucose induced reduction of
cardiomyocyte AdipoR2 protein expression can be restored by
APN. The results suggest that cardiac APN may be a major
contributor to the restoration of cardiac AdipoR2 expression in
diabetes.
AMPK can be activated by APN via APN receptors [46].
However, our results showed that cardiac phosphorylation of
AMPK-a was increased in diabetic rats at the early stage and this
was accompanied by increased phosphorylation of downstream
protein ACC despite reduction in cardiac APN and AdipoR2. It is
possible that AdipoR1 activation plays a dominant role in APN
mediated AMPK-a activation in early diabetes. It is also possible
that diabetes-related hypoxia activated AMPK as reported [47].
NAC and/or ALP decreased phosphorylation of AMPK-a and
ACC in diabetic rats, potentially as a result of attenuating
oxidative stress or diabetic myocardial hypoxia. Although APN
deficiency may lead to the inactivation of AMPK [48], which is
contradictory to our finding, recent studies indeed suggest that the
role of AMPK in cardiac function is controversial and AMPK
activation may either be beneficial or detrimental to the ischemic
heart [49]. The timing and magnitude of AMPK activation may
determine the effectiveness of AMPK cardiac protection. In our
study, antioxidant treatments attenuated the dramatic increase in
AMPK activation, while maintaining its activation at a level
moderately higher than that in the control group and led to
beneficial cardioprotective effects. It has been well established that
AMPK is the main kinase regulator of ACC, able to phosphorylate
and inactivate ACC [50]. Excessive cardiac ACC phosphorylation
by AMPK increases fatty acid oxidation which may exacerbate
postischemic myocardial injury [51]. In our studies, NAC and
ALP combination most prominently reduced both p-AMPK-a and
p-ACC level in diabetic rats and resulted in most significant
reduction of postischemic myocardial infarction in diabetes.
We have shown that APN can induce eNOS activation and
increase NO production in human endothelial cells [28], prevent
diabetic premature senescence of endothelial progenitor cells and
promote endothelial repair [52]. The reperfusion injury signaling
kinase (RISK) pathway including PI3K/Akt signaling cascade and
the protective survivor activating factor enhancement (SAFE)
pathway including JAK2/STAT3 signaling cascade are the most
important pathways involved in eNOS activation and ischemia
myocardial protection [53] [54]. Activation of Akt has been
implicated in the control of skeletal muscle hypertrophy [55]. APN
can also activate STAT3 in adult mouse cardiac fibroblasts [56].
Akt and JAK/STAT are congenerous pathways through which
oxidative stress downregulates APN in 3T2-L1 preadipocyte cells
[57]. Our studies showed that cardiac phosphorylation of Akt and
STAT3 were decreased significantly in diabetic rats at the early
stage followed by decreased eNOS activation. Both NAC and ALP
significantly restored diabetic Akt and eNOS phosphorylation,
while the combination conferred a synergistic effect. NAC alone
significantly restored STAT3 phosphorylation. In contrast, ALP
alone had no effect on STAT3 phosphorylation in diabetic rats,
which was coincident with its inability to restore APN and
AdipoR2 protein expression in diabetic rat hearts. Our results
suggest that the antioxidants NAC and ALP may have conferred
myocardial protection respectively primarily via the SAFE and/or
the RISK pathways. Although cross-talk may exist between the
RISK and SAFE pathways [54], they can work independently in
mediating cardioprotection. Studies have reported that TNF-a,a t
moderately elevated concentrations, initiate the activation of
SAFE pathway leading to cardioprotection [58], although at high
concentrations TNF-a exert detrimental effects. In our study, ALP
unexpectedly compromised the effect of NAC in reducing plasma
TNF-a, such that the plasma TNF-a in the D+N+A group was
lower than that in the diabetic group but yet higher than that in
the non-diabetic control or NAC treated diabetic group, which
resulted in the most prominent myocardial STAT3 phosphoryla-
tion and reduction of postischemic myocardial infarction in the
D+N+A group. Although the underlying mechanism governing
the synergy or interaction between NAC and ALP is yet to be
investigated, our findings seem to be in agreement with the notion
that moderate levels of TNF-a can stimulate the activation of
SAFE pathway and thus confer cardioprotection [58].
Recently, it has been shown that low plasma APN is a clinical
risk factor for myocardial infarction [59]. APN confers resistance
to acute MI/R injury [14]. The restoration of cardiac APN levels
after antioxidant treatment may contribute to the attenuation of
postischemic myocardial infarction and cellular injury as well as
hemodynamic improvement in diabetic rats because APN has
beneficial actions on the cardiovascular system by directly acting
on the heart and blood vessels [55]. Interestingly, a combination of
NAC and ALP displayed a synergistic cardioprotective effect,
which reinforces a strategy to use a combination of, rather than a
single antioxidant, to inhibit ROS via different mechanisms. This
study demonstrates for the first time the relationship between
antioxidants, APN and MI/R injury. The results suggest that
antioxidants modulate APN content, which may in turn enhance
their cardioprotective effect.
In summary, this study demonstrated that, in the early stages of
STZ-induced diabetes, rats displayed APN deficiency and
increased inflammatory cytokines together with reduced cardiac
AdipoR2 expression and impaired Akt-eNOS and STAT3-eNOS
activation. The combination of NAC and ALP confer a synergistic
effect on restoration of APN content and AdipoR2 mediated
eNOS activation, which is a potential mechanism for enhancing
the resistance to MI/R injury in the early stage of diabetes. Results
from the present study provide insight into the effects and
mechanisms of antioxidants synergy which may lead to the
development of effective therapeutic regimens to combat diabetic
myocardial complications.
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